Complete remission of minimal change nephrotic syndrome with type 2 diabetes mellitus treated by microemulsion formulation of cyclosporin and fluvastatin

Japanese Journal of Nephrology

Volumn 44, Issue 2, 2002, Pages 109-113

  Makibayashi, Kojiro ^a   Fukatsu, Atsushi ^b   Kita, Toru ^b  

^a Department of Urology   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Fluvastatin; Microemulsion formulation of cyclosporin (Neoral ); Minimal change nephrotic syndrome; Type 2 diabetes mellitus

Indexed keywords

ANTIBIOTIC AGENT; CHOLESTEROL; CYCLOSPORIN A; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG ABSORPTION; HUMAN; HYPERLIPIDEMIA; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; LIPID METABOLISM; MALE; MICROEMULSION; MINIMAL CHANGE NEPHROTIC SYNDROME; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CYCLOSPORINE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EMULSIONS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; MALE; MIDDLE AGED; NEPHROSIS, LIPOID; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0036241376     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Di Padova FE. Pharmacology of cyclosporine (Sandimmune) V. Pharmacological effects on immune function : in vitro studies. Pharmacol Rev 1989 ; 41 : 373-405.
2. Ramjee G, Coovadia HM, Adhikari M. Direct and indirect tests of pore size and charge selectivity in nephrotic syndrome. J Lab Clin Med 1996 ; 127 : 195-9.
3. Heslan JMJ, Branellec AI, Pilatte Y, Lang P, Lagrue G. Differentiation between vascular permeability factor and IL-2 in lymphocyte suspernatants from patients with minimal-change nephrotic syndrome. Clin Exp Immunol 1991 ; 86 : 157-62.
4. Tejani A, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar MR. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 1988 ; 33 : 729-34.
5. Clasen W, Kindler J, Mihatsch MJ, Sieberth HG. Long-term treatment of minimal-change nephrotic syndrome with cyclosporin : a control biopsy study. Nephrol Dial Transplant 1988 ; 3 : 733-7.
6. Webb KL, Sargent P, Burke JR. Cyclosporin therapy in steroid-dependent nephrotic syndrome. J Pacdiatr 1993 ; 29 : 188-91.
7. Miyazaki M, Harada T, Ozono Y, Kohno S. Use of Cyclosporin A(Cyclosporine) for pediatric and adult patients with nephrotic sydrome : Experience of nephrologists in western Japan. Clin Exp Nephrol 1999 ; 3 : 48-54.
8. Joven J, Villabona C, Vilella E, Masana L. Alberti R, Valles M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990 ; 323 : 579-84.
9. De Groen PC. Cyclosporine. low-density lipoprotein. and cholesterol. Mayo Clin Proc 1988 ; 63 : 1012-21.
10. Ingulli E, Tejani A. Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome. J Am Soc Nephrol 1992 ; 3 : 254-9.
11. Nakamura T, Nishi H, Kokusenya Y, Hirota K, Miura Y. Mechanism of antioxidative activity of fluvastatin-determination of the active position. Chem Pharm Bull 2000 ; 48 : 235-7.
12. Holdaas H, Hartmann A, Stenstrom J, Dahl KJ, Borge M, Pharm MSc, Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995 ; 76 : 102A-6.
13. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999 ; 84 : 413-28.
14. Bio Clinica 1996 ; 11 : 988-94